Therapy for EBV-associated tumors
Promoting growth
Long-term partner for start-ups
We have already accompanied over 100 start-up projects. We usually acquire a minority share in the resulting companies.
We continue to support our portfolio companies on their growth trajectory and manage our shares as profitably as possible until exit – or, in the case of floatation or takeovers by listed companies, beyond.
We distribute most of our revenues from the sale of equity and shares to the LifeScience Foundation, which in turn makes them available to its endowing institutes as research grants
Current shareholdings
Zelltechs
Former shareholdings
Activaero GmbH
Bioregeneration GmbH
BITZ GmbH
Clueda AG
eADMET GmbH
Encepharm GmbH
Genomatix GmbH
Inamed GmbH
SurgVision B.V.
Trianta Immunotherapies GmbH
TRION Pharma GmbH
Vakzine Projekt Management GmbH
WBC Drug Delivery Technologies
Zellkraftwerk GmbH
Activaero GmbH
Alerion
amcure GmbH
BigChem GmbH
Biomax AG
Bioregeneration GmbH
BITZ GmbH
Canopy Biosciences
Consentris GmbH
Clueda AG
CoImmune
DentalXrai
eADMET GmbH
Encepharm GmbH
Genomatix GmbH
Inamed GmbH
NanoRepro AG
Spero Therapeutics LLC
SurgVision B.V.
Trianta Immunotherapies GmbH
TRION Pharma GmbH
Tube Pharmaceutical GmbH
Vakzine Projekt Management GmbH
Vectura Group plc
WBC Drug Delivery Technologies
Zellkraftwerk GmbH
amcure GmbH
DentalXrai
Vectura Group plc
Consentris GmbH
Tube Pharmaceutical GmbH
WBC Drug Delivery Technologies
CoImmune